Can we refine strategy on HDL by new pharmacological approaches?
EAS Academy. Chapman J. 10/06/17; 200945 Topic: Therapy
Prof. John Chapman
Prof. John Chapman

Access to Premium Content is a benefit of Individual EAS membership. Apply for membership


Access EAS content "anytime, anywhere" with the EAS Academy App for iOS and Android


For any questions contact us at office@eas-society.org

Discussion Forum (0)
Rate & Comment (0)
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies